Profile data is unavailable for this security.
About the company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
- Revenue in SEK (TTM)0.00
- Net income in SEK-31.16m
- Incorporated2008
- Employees4.00
- LocationIsofol Medical AB (publ)Biotech Center, Arvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317972280
- Fax+46 317411701
- Websitehttps://isofolmedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Opticept Technologies AB | 9.15m | -80.36m | 87.79m | 29.00 | -- | 0.1926 | -- | 9.60 | -2.62 | -2.62 | 0.2981 | 10.80 | 0.0213 | -0.0638 | 2.37 | 315,344.80 | -18.69 | -41.76 | -21.19 | -46.21 | 125.88 | 62.65 | -879.63 | -882.41 | 0.6163 | -14.16 | 0.0566 | -- | -12.90 | 49.17 | 19.80 | -- | 45.22 | -- |
| Bioextrax AB publ | 2.06m | -21.51m | 88.72m | -- | -- | 3.70 | -- | 43.13 | -0.8026 | -0.8026 | 0.0769 | 0.6968 | 0.0681 | -- | 124.67 | -- | -71.17 | -86.39 | -82.24 | -110.84 | 34.95 | -- | -1,045.50 | -2,119.90 | -- | -- | 0.00 | -- | 420.51 | 24.40 | -15.21 | -- | 56.86 | -- |
| Ziccum AB | 6.64m | -20.50m | 90.39m | 9.00 | -- | 6.89 | -- | 13.62 | -1.46 | -1.46 | 0.4721 | 0.8534 | 0.2696 | -- | 22.01 | 829,375.00 | -83.29 | -68.51 | -106.42 | -76.47 | -- | -- | -308.94 | -2,598.03 | -- | -- | 0.0516 | -- | -- | 75.20 | 25.62 | -- | -13.45 | -- |
| AroCell AB (publ) | 44.79m | -56.13m | 90.99m | -- | -- | 0.5942 | -- | 2.03 | -0.2437 | -0.2437 | 0.1944 | 0.6648 | 0.2325 | 5.82 | 5.63 | -- | -29.14 | -29.25 | -31.00 | -31.37 | 1.88 | -9.85 | -125.33 | -231.19 | 5.16 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Wntresearch AB | 0.00 | -35.82m | 93.53m | 2.00 | -- | 2.30 | -- | -- | -0.0919 | -0.0919 | 0.00 | 0.047 | 0.00 | -- | -- | 0.00 | -89.47 | -100.71 | -103.70 | -123.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.65 | -- | -- | -- |
| Bio-Works Technologies AB | 43.90m | -56.82m | 99.40m | 38.00 | -- | 2.26 | -- | 2.26 | -1.58 | -1.58 | 1.22 | 1.13 | 0.571 | 1.82 | 5.83 | 1,155,158.00 | -73.91 | -49.14 | -101.72 | -57.90 | 61.10 | 69.88 | -129.44 | -168.30 | 2.79 | -- | 0.00 | -- | 6.23 | 46.24 | -26.41 | -- | 1.95 | -- |
| Bactiquant A/S | 19.14m | -20.38m | 111.12m | -- | -- | 4.96 | -- | 5.81 | -0.6358 | -0.6358 | 0.5971 | 0.6133 | 0.5055 | 3.67 | 2.83 | -- | -53.83 | -41.26 | -62.59 | -47.16 | -6.14 | 12.89 | -106.51 | -71.77 | 5.43 | -8.54 | 0.0431 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| New Nordic Healthbrands AB | 537.81m | -10.17m | 112.13m | 70.00 | -- | 1.07 | -- | 0.2085 | -1.64 | -1.64 | 86.81 | 16.86 | 2.16 | 1.84 | 4.96 | 7,367,219.00 | -4.09 | 5.36 | -9.16 | 10.55 | 65.32 | 67.30 | -1.89 | 2.38 | 0.8584 | -4.44 | 0.2821 | 47.96 | 9.51 | 6.28 | -119.41 | -- | 28.36 | -- |
| Toleranzia AB | 0.00 | -7.46m | 114.30m | 7.00 | -- | 0.7446 | -- | -- | -0.0542 | -0.0542 | 0.00 | 0.779 | 0.00 | -- | -- | 0.00 | -5.22 | -7.45 | -5.43 | -7.78 | -- | -- | -- | -- | -- | -- | 0.0055 | -- | -- | -- | 11.79 | -- | 63.90 | -- |
| Odi Pharma AB (publ) | 818.38k | -3.97m | 114.91m | -- | -- | 56.43 | -- | 140.41 | -0.2608 | -0.2608 | 0.0538 | 0.1338 | 0.1084 | 1.22 | 6.98 | -- | -52.58 | -- | -95.24 | -- | -53.07 | -- | -484.96 | -- | 1.32 | -14.10 | 0.00 | -- | -55.44 | -- | 4.67 | -- | -- | -- |
| Isofol Medical AB (publ) | 0.00 | -31.16m | 115.48m | 4.00 | -- | 1.02 | -- | -- | -0.1964 | -0.1964 | 0.00 | 0.6993 | 0.00 | -- | -- | 0.00 | -20.49 | -66.73 | -24.10 | -88.27 | -- | -- | -- | -1,023.62 | -- | -- | 0.00 | -- | -94.37 | -- | 76.80 | -- | -- | -- |
| Biovica International AB | 5.98m | -122.99m | 123.99m | 37.00 | -- | 0.985 | -- | 20.74 | -2.42 | -2.42 | 0.115 | 1.62 | 0.033 | -0.3053 | 8.43 | 170,800.00 | -67.80 | -42.10 | -74.69 | -46.33 | 110.09 | 277.88 | -2,057.41 | -2,149.68 | 7.10 | -- | 0.057 | -- | 65.43 | 4.44 | -84.14 | -- | -20.20 | -- |
| Lipum AB (publ) | 0.00 | -37.18m | 136.82m | 5.00 | -- | 13.65 | -- | -- | -4.38 | -4.38 | 0.00 | 0.4726 | 0.00 | -- | -- | 0.00 | -159.35 | -127.85 | -206.31 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | 0.2781 | -- | -- | -- | 2.38 | -- | -- | -- |
| Circa Group AS | 19.10m | -73.28m | 136.93m | 17.00 | -- | 0.3915 | -- | 7.17 | -0.6732 | -0.6732 | 0.1729 | 2.87 | 0.0403 | 5.46 | 0.9139 | 1,124,460.00 | -15.46 | -- | -19.96 | -- | 75.64 | -- | -383.72 | -- | 0.7097 | -- | 0.00 | -- | 41.73 | -- | -0.0491 | -- | -- | -- |
| Xintela AB | 78.00k | -54.09m | 142.32m | -- | -- | 32.49 | -- | 1,824.60 | -0.1524 | -0.1524 | 0.0002 | 0.0077 | 0.0036 | -- | 0.0088 | -- | -252.09 | -181.06 | -1,065.04 | -391.61 | 100.00 | -- | -69,343.59 | -235,894.00 | -- | -50.47 | 0.00 | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| StenoCare A/S | 6.38m | -26.15m | 142.70m | 9.00 | -- | 4.09 | -- | 22.35 | -1.13 | -1.13 | 0.2674 | 1.22 | 0.1285 | -- | 2.94 | -- | -52.62 | -28.16 | -70.34 | -35.47 | -- | -- | -409.55 | -371.06 | 1.04 | -5.56 | 0.2362 | -- | -16.30 | -- | -7.77 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Isofol Medical AB (publ)'s reporting currency: Swedish Krona SEK
5.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 24 Aug 2022 | 8.29m | 5.13% |
| SEB Investment Management ABas of 30 Apr 2024 | 1.02m | 0.63% |
| Skandia Investment Management ABas of 29 Feb 2024 | 159.45k | 0.10% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
